Published in Semin Immunopathol on April 01, 2007
Neuroendocrine nicotinic receptor activation increases susceptibility to bacterial infections by suppressing antimicrobial peptide production. Cell Host Microbe (2010) 2.39
Corruption of innate immunity by bacterial proteases. J Innate Immun (2009) 1.96
Antimicrobial peptides. Pharmaceuticals (Basel) (2013) 1.37
The role of antimicrobial peptides at the ocular surface. Ophthalmic Res (2008) 1.32
The outer frontier: the importance of lipid metabolism in the skin. J Lipid Res (2008) 1.16
Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment. PLoS One (2009) 1.16
Identification of the cathelicidin peptide LL-37 as agonist for the type I insulin-like growth factor receptor. Oncogene (2011) 1.09
Toll-like receptors in ocular surface disease. Exp Eye Res (2010) 1.05
Defensins as anti-inflammatory compounds and mucosal adjuvants. Future Microbiol (2010) 0.95
Streptococcal inhibitor of complement promotes innate immune resistance phenotypes of invasive M1T1 group A Streptococcus. J Innate Immun (2010) 0.94
Salivary antimicrobial peptides (LL-37 and alpha-defensins HNP1-3), antimicrobial and IgA responses to prolonged exercise. Eur J Appl Physiol (2009) 0.93
Two chromogranin a-derived peptides induce calcium entry in human neutrophils by calmodulin-regulated calcium independent phospholipase A2. PLoS One (2009) 0.93
Antimicrobial activity of pure platelet-rich plasma against microorganisms isolated from oral cavity. BMC Microbiol (2013) 0.93
Expression of epidermal CAMP changes in parallel with permeability barrier status. J Invest Dermatol (2011) 0.90
Temporin-SHf, a new type of phe-rich and hydrophobic ultrashort antimicrobial peptide. J Biol Chem (2010) 0.88
Cationic antimicrobial peptides serve as activation signals for the Salmonella Typhimurium PhoPQ and PmrAB regulons in vitro and in vivo. Front Cell Infect Microbiol (2012) 0.87
Molecular Design, Structural Analysis and Antifungal Activity of Derivatives of Peptide CGA-N46. Interdiscip Sci (2016) 0.87
Sulfolipid-1 biosynthesis restricts Mycobacterium tuberculosis growth in human macrophages. ACS Chem Biol (2012) 0.87
Paradoxical benefits of psychological stress in inflammatory dermatoses models are glucocorticoid mediated. J Invest Dermatol (2014) 0.86
Cholinergic regulation of keratinocyte innate immunity and permeability barrier integrity: new perspectives in epidermal immunity and disease. J Invest Dermatol (2011) 0.85
The Oral Microbiome of Denture Wearers Is Influenced by Levels of Natural Dentition. PLoS One (2015) 0.84
Fitness level impacts salivary antimicrobial protein responses to a single bout of cycling exercise. Eur J Appl Physiol (2015) 0.84
Role of host-defence peptides in eye diseases. Cell Mol Life Sci (2011) 0.84
Plasma components and platelet activation are essential for the antimicrobial properties of autologous platelet-rich plasma: an in vitro study. PLoS One (2014) 0.84
Defensins attenuate cytokine responses yet enhance antibody responses to Porphyromonas gingivalis adhesins in mice. Future Microbiol (2010) 0.83
An altered immune response, but not individual cationic antimicrobial peptides, is associated with the oral attenuation of Ara4N-deficient Salmonella enterica serovar Typhimurium in mice. PLoS One (2012) 0.83
Antimicrobial anxiety: the impact of stress on antimicrobial immunity. J Leukoc Biol (2010) 0.83
Cathelicidin antimicrobial peptide expression is not induced or required for bacterial clearance during salmonella enterica infection of human monocyte-derived macrophages. Infect Immun (2012) 0.82
Local Burn Injury Promotes Defects in the Epidermal Lipid and Antimicrobial Peptide Barriers in Human Autograft Skin and Burn Margin: Implications for Burn Wound Healing and Graft Survival. J Burn Care Res (2016) 0.80
Bioactivity and the first transmission electron microscopy immunogold studies of short de novo-designed antimicrobial peptides. Antimicrob Agents Chemother (2011) 0.80
Distinct profiling of antimicrobial peptide families. Bioinformatics (2014) 0.80
Bactericidal efficiency and modes of action of the novel antimicrobial peptide T9W against Pseudomonas aeruginosa. Antimicrob Agents Chemother (2015) 0.78
Innate barriers against infection and associated disorders. Drug Discov Today Dis Mech (2008) 0.78
Esculentin-1a(1-21)NH2: a frog skin-derived peptide for microbial keratitis. Cell Mol Life Sci (2014) 0.78
Upregulation of human β-defensin-3 and cathelicidin LL-37 in Kaposi's sarcoma. F1000Res (2012) 0.77
Integrating "omics" Technologies to Conceptualize Dynamic Antimicrobial Peptide Responses. Front Immunol (2012) 0.77
Identification and Characterization of the First Cathelicidin from Sea Snakes with Potent Antimicrobial and Anti-inflammatory Activity and Special Mechanism. J Biol Chem (2015) 0.77
Cathelicidins from the bullfrog Rana catesbeiana provides novel template for peptide antibiotic design. PLoS One (2014) 0.77
Morphological changes induced by the action of antimicrobial peptides on supported lipid bilayers. J Phys Chem B (2010) 0.77
Antimicrobial Peptides can Enhance the Risk of Persistent Infections. Front Immunol (2012) 0.76
Overexpression of an antimicrobial peptide derived from C. elegans using an aggregation-prone protein coexpression system. AMB Express (2013) 0.76
Keratinocyte nicotinic acetylcholine receptor activation modulates early TLR2-mediated wound healing responses. Int Immunopharmacol (2015) 0.75
Screening and Optimizing Antimicrobial Peptides by Using SPOT-Synthesis. Front Chem (2017) 0.75
Efficacy of the combination of tachyplesin III and clarithromycin in rat models of Escherichia coli sepsis. Antimicrob Agents Chemother (2008) 0.75
Protection efficacy of the Brucella abortus ghost vaccine candidate lysed by the N-terminal 24-amino acid fragment (GI24) of the 36-amino acid peptide PMAP-36 (porcine myeloid antimicrobial peptide 36) in murine models. J Vet Med Sci (2016) 0.75
Cutaneous Burn Injury Modulates Urinary Antimicrobial Peptide Responses and the Urinary Microbiome. Crit Care Med (2017) 0.75
Antimicrobial peptides of multicellular organisms. Nature (2002) 23.50
Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol (2005) 13.69
Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol (2003) 11.11
Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med (2002) 9.01
Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest (1985) 8.63
Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc Natl Acad Sci U S A (1987) 8.53
Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science (1999) 7.86
A peptide antibiotic from human skin. Nature (1997) 7.64
Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell (1996) 6.84
Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature (2001) 6.71
Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science (1999) 6.49
Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J Biol Chem (1999) 6.44
Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol (2004) 6.35
Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell (1997) 5.99
Sequence and specificity of two antibacterial proteins involved in insect immunity. Nature (1981) 5.66
The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nat Med (2006) 5.20
Mammalian defensins in the antimicrobial immune response. Nat Immunol (2005) 4.84
A component of innate immunity prevents bacterial biofilm development. Nature (2002) 4.73
The chromogranin-secretogranin family. N Engl J Med (2003) 4.28
Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat Rev Immunol (2006) 4.05
Paneth cells of the human small intestine express an antimicrobial peptide gene. J Biol Chem (1992) 4.04
Antimicrobial defensin peptides form voltage-dependent ion-permeable channels in planar lipid bilayer membranes. Proc Natl Acad Sci U S A (1990) 3.90
The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J Biol Chem (1997) 3.82
Human beta-defensin-1: an antimicrobial peptide of urogenital tissues. J Clin Invest (1998) 3.78
Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Invest (1998) 3.51
Channel-forming properties of cecropins and related model compounds incorporated into planar lipid membranes. Proc Natl Acad Sci U S A (1988) 3.51
Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood (2001) 3.49
Widespread expression of beta-defensin hBD-1 in human secretory glands and epithelial cells. FEBS Lett (1996) 3.39
Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J Invest Dermatol (2001) 3.39
Expression and regulation of the human beta-defensins hBD-1 and hBD-2 in intestinal epithelium. J Immunol (1999) 3.39
Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett (1995) 3.21
An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest (2003) 3.19
Antimicrobial psoriasin (S100A7) protects human skin from Escherichia coli infection. Nat Immunol (2004) 3.19
Downregulation of bactericidal peptides in enteric infections: a novel immune escape mechanism with bacterial DNA as a potential regulator. Nat Med (2001) 3.11
Neuroendocrine regulation of immunity. Annu Rev Immunol (2001) 3.11
Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37. J Biol Chem (1998) 2.91
FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis. Proc Natl Acad Sci U S A (1995) 2.89
Defensin-6 mRNA in human Paneth cells: implications for antimicrobial peptides in host defense of the human bowel. FEBS Lett (1993) 2.82
Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4. J Clin Invest (2001) 2.78
Discovery of five conserved beta -defensin gene clusters using a computational search strategy. Proc Natl Acad Sci U S A (2002) 2.56
Antimicrobial peptides human beta-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines. J Invest Dermatol (2006) 2.53
Human beta-defensin 4: a novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity. FASEB J (2001) 2.52
The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol (2003) 2.50
Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction. Cell Tissue Res (2001) 2.45
Identification of CRAMP, a cathelin-related antimicrobial peptide expressed in the embryonic and adult mouse. J Biol Chem (1997) 2.38
Mechanisms of action on Escherichia coli of cecropin P1 and PR-39, two antibacterial peptides from pig intestine. Infect Immun (1993) 2.37
Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureus-derived proteinases. Antimicrob Agents Chemother (2004) 2.34
Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J (2006) 2.33
Dermcidin: a novel human antibiotic peptide secreted by sweat glands. Nat Immunol (2001) 2.29
Coordinate induction of two antibiotic genes in tracheal epithelial cells exposed to the inflammatory mediators lipopolysaccharide and tumor necrosis factor alpha. Infect Immun (1996) 2.20
Human beta-defensin-2. Int J Biochem Cell Biol (1999) 2.19
Selective killing of vaccinia virus by LL-37: implications for eczema vaccinatum. J Immunol (2004) 2.16
Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc Natl Acad Sci U S A (2002) 2.14
Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides. Infect Immun (2004) 2.14
Syndecans, cell surface heparan sulfate proteoglycans, are induced by a proline-rich antimicrobial peptide from wounds. Proc Natl Acad Sci U S A (1994) 2.02
Insect defensin, an inducible antibacterial peptide, forms voltage-dependent channels in Micrococcus luteus. J Biol Chem (1993) 2.02
Mouse neutrophils lack defensins. Infect Immun (1992) 2.01
RNase 7, a novel innate immune defense antimicrobial protein of healthy human skin. J Biol Chem (2002) 1.99
Mouse Paneth cell defensins: primary structures and antibacterial activities of numerous cryptdin isoforms. Infect Immun (1994) 1.93
Control of the innate epithelial antimicrobial response is cell-type specific and dependent on relevant microenvironmental stimuli. Immunology (2006) 1.88
Neutrophil defensins: purification, characterization, and antimicrobial testing. Methods Enzymol (1994) 1.88
Cathelicidin mediates innate intestinal defense against colonization with epithelial adherent bacterial pathogens. J Immunol (2005) 1.86
Perturbation of the hydrophobic core of lipid bilayers by the human antimicrobial peptide LL-37. Biochemistry (2004) 1.86
Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest (1997) 1.86
Cutaneous defense mechanisms by antimicrobial peptides. J Invest Dermatol (2005) 1.85
Antimicrobial peptides in animals and their role in host defences. Int J Antimicrob Agents (2003) 1.84
Regulation of dendritic cell trafficking: a process that involves the participation of selective chemokines. J Leukoc Biol (1999) 1.84
Cell differentiation is a key determinant of cathelicidin LL-37/human cationic antimicrobial protein 18 expression by human colon epithelium. Infect Immun (2002) 1.80
Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J Immunol (2003) 1.79
The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J Immunol (2004) 1.78
Zinc-reversible antimicrobial activity of recombinant calprotectin (migration inhibitory factor-related proteins 8 and 14). J Infect Dis (2000) 1.76
Postsecretory processing generates multiple cathelicidins for enhanced topical antimicrobial defense. J Immunol (2004) 1.74
Antimicrobial effects of alpha-MSH peptides. J Leukoc Biol (2000) 1.74
Biology and clinical relevance of naturally occurring antimicrobial peptides. J Allergy Clin Immunol (2002) 1.71
Direct bacterial protein PAMP recognition by human NK cells involves TLRs and triggers alpha-defensin production. Blood (2004) 1.71
Antimicrobial and protease inhibitory functions of the human cathelicidin (hCAP18/LL-37) prosequence. J Invest Dermatol (2003) 1.70
Mechanism of antimicrobial action of indolicidin. FEMS Microbiol Lett (1998) 1.70
Posttranslational processing of defensins in immature human myeloid cells. Blood (1992) 1.68
The mammalian ionic environment dictates microbial susceptibility to antimicrobial defense peptides. FASEB J (2006) 1.66
Human alpha- and beta-defensins block multiple steps in herpes simplex virus infection. J Immunol (2006) 1.64
The nervous system and innate immunity: the neuropeptide connection. Nat Immunol (2005) 1.63
Structure-activity analysis of buforin II, a histone H2A-derived antimicrobial peptide: the proline hinge is responsible for the cell-penetrating ability of buforin II. Proc Natl Acad Sci U S A (2000) 1.62
Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. Eur J Gastroenterol Hepatol (2002) 1.59
Mouse beta-defensin 3 is an inducible antimicrobial peptide expressed in the epithelia of multiple organs. Infect Immun (1999) 1.58
Identification of multiple novel epididymis-specific beta-defensin isoforms in humans and mice. J Immunol (2002) 1.53
Primary structure of a new cysteine proteinase inhibitor from pig leucocytes. FEBS Lett (1989) 1.50
Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model. J Clin Invest (1999) 1.50
Human alpha-defensins block papillomavirus infection. Proc Natl Acad Sci U S A (2006) 1.48
Keratinocytes store the antimicrobial peptide cathelicidin in lamellar bodies. J Invest Dermatol (2005) 1.48
How bacteria resist killing by host-defense peptides. Trends Microbiol (1994) 1.48
Staphylococcal resistance to antimicrobial peptides of mammalian and bacterial origin. Peptides (2001) 1.47
Cathelicidin anti-microbial peptide expression in sweat, an innate defense system for the skin. J Invest Dermatol (2002) 1.47
Current status of defensins and their role in innate and adaptive immunity. FEMS Microbiol Lett (2002) 1.42
Evolution of primate theta-defensins: a serpentine path to a sweet tooth. Peptides (2003) 1.42
Differential regulation of beta-defensin expression in human skin by microbial stimuli. J Immunol (2005) 1.41
Induction of the antimicrobial peptide CRAMP in the blood-brain barrier and meninges after meningococcal infection. Infect Immun (2006) 1.41
Homodimeric theta-defensins from rhesus macaque leukocytes: isolation, synthesis, antimicrobial activities, and bacterial binding properties of the cyclic peptides. J Biol Chem (2001) 1.41
Expression of the peptide antibiotics human beta defensin-1 and human beta defensin-2 in normal human skin. J Invest Dermatol (2001) 1.37
Antimicrobial peptides: an essential component of the skin defensive barrier. Curr Top Microbiol Immunol (2006) 1.36
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med (2006) 5.07
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial. JACC Cardiovasc Interv (2009) 1.56
Determining the in-hospital cost of bleeding in patients undergoing percutaneous coronary intervention. J Interv Cardiol (2009) 1.47
Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY. Int J Cardiol (2009) 1.45
Differential 1-year clinical outcomes for ST-segment elevation myocardial infarction related to stent thrombosis or saphenous vein graft thrombosis. Catheter Cardiovasc Interv (2013) 1.38
Cathelicidin is involved in the intracellular killing of mycobacteria in macrophages. Cell Microbiol (2011) 1.17
The antimicrobial peptide LL-37 modulates the inflammatory and host defense response of human neutrophils. Eur J Immunol (2010) 1.12
Laboratory-acquired brucellosis. Emerg Infect Dis (2004) 1.12
Cathelicidin signaling via the Toll-like receptor protects against colitis in mice. Gastroenterology (2011) 1.09
Validation of the Global Registry of Acute Coronary Event (GRACE) risk score for in-hospital mortality in patients with acute coronary syndrome in Canada. Am Heart J (2009) 1.07
CC chemokine ligand 3 overcomes the bacteriocidal and phagocytic defect of macrophages and hastens recovery from experimental otitis media in TNF-/- mice. J Immunol (2010) 0.98
Development and validation of a bleeding risk model for patients undergoing elective percutaneous coronary intervention. Int J Cardiol (2010) 0.95
An innate bactericidal oleic acid effective against skin infection of methicillin-resistant Staphylococcus aureus: a therapy concordant with evolutionary medicine. J Microbiol Biotechnol (2011) 0.89
Temporal changes in the management and outcome of Canadian diabetic patients hospitalized for non-ST-elevation acute coronary syndromes. Am Heart J (2011) 0.89
Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal. Catheter Cardiovasc Interv (2007) 0.89
Role of rheolytic thrombectomy in massive pulmonary embolism with contraindication to systemic thrombolytic therapy. EuroIntervention (2010) 0.88
Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. Int J Cardiol (2008) 0.85
Guideline adjudicated fibrinolytic failure: incidence, findings, and management in a contemporary clinical trial. Am Heart J (2007) 0.85
Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial. Eur Heart J (2008) 0.85
Effect on bleeding, time to revascularization, and one-year clinical outcomes of the radial approach during primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Am J Cardiol (2010) 0.85
Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea. Cutis (2014) 0.83
Demographics, treatment and outcome of acute coronary syndromes: 17 years of experience in a specialized cardiac centre. Can J Cardiol (2006) 0.83
Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents. Cutis (2013) 0.83
Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials. Arch Intern Med (2007) 0.82
Temporal trends and patterns of early clopidogrel use across the spectrum of acute coronary syndromes. Am Heart J (2009) 0.81
Prognostic significance of elevated creatine kinase MB after coronary bypass surgery and after an acute coronary syndrome: results from the GUARDIAN trial. J Thorac Cardiovasc Surg (2003) 0.81
Relation between previous angiotensin-converting enzyme inhibitor use and in-hospital outcomes in acute coronary syndromes. Am J Cardiol (2011) 0.81
The association between prior use of aspirin and/or warfarin and the in-hospital management and outcomes in patients presenting with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). Can J Cardiol (2011) 0.81
Canadian Cardiovascular Society position statement on radiation exposure from cardiac imaging and interventional procedures. Can J Cardiol (2013) 0.80
Use and timing of coronary angiography and associated in-hospital outcomes in Canadian non-ST-segment elevation myocardial infarction patients: insights from the Canadian Global Registry of Acute Coronary Events. Can J Cardiol (2013) 0.80
Reperfusion strategies and outcomes of ST-segment elevation myocardial infarction patients in Canada: observations from the Global Registry of Acute Coronary Events (GRACE) and the Canadian Registry of Acute Coronary Events (CANRACE). Can J Cardiol (2011) 0.80
Finite element modeling of a progressively expanding shape memory stent. J Biomech (2005) 0.79
Evaluation of left ventricular ejection fraction in non-ST-segment elevation acute coronary syndromes and its relationship to treatment. Am Heart J (2010) 0.79
Prognostic significance of presenting blood pressure in non-ST-segment elevation acute coronary syndrome in relation to prior history of hypertension. Am Heart J (2013) 0.78
Effects of P-Selectin Antagonist Inclacumab in Patients Undergoing Coronary Artery Bypass Graft Surgery: SELECT-CABG Trial. J Am Coll Cardiol (2016) 0.78
Consensus recommendations from the American acne & rosacea society on the management of rosacea, part 4: a status report on physical modalities and devices. Cutis (2014) 0.77
Use of clopidogrel post-coronary artery bypass surgery in canadian patients with acute coronary syndromes. Can J Cardiol (2011) 0.76
Effect of irbesartan and enalapril in non-ST elevation acute coronary syndrome: results of the randomized, double-blind ARCHIPELAGO study. Eur Heart J (2009) 0.76
Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment. Can J Cardiol (2006) 0.75
Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 3: a status report on systemic therapies. Cutis (2014) 0.75
Endocardial cryotherapy as a novel strategy of improving myocardial perfusion in a patient with severe coronary artery disease. Catheter Cardiovasc Interv (2003) 0.75
Internal thoracic artery dissection: a proposed mechanistic explanation. JACC Cardiovasc Interv (2013) 0.75
Treatment and outcomes of non-ST elevation acute coronary syndromes in relation to burden of pre-existing vascular disease. Int J Cardiol (2013) 0.75
Multimodal imaging study of a thrombosed right coronary artery aneurysm. Rev Esp Cardiol (2009) 0.75
In vivo measurement of coronary circulation angiotensin-converting enzyme activity in humans. Am J Physiol Heart Circ Physiol (2003) 0.75